V 212

Drug Profile

V 212

Alternative Names: Inactivated varicella-zoster vaccine - Merck; V212; Varicella zoster virus vaccine - Merck; VZV vaccine - Merck

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Class Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Herpes zoster

Most Recent Events

  • 29 May 2015 No recent reports on development identified - Phase-II for Herpes zoster (Prevention) in Australia, Canada, Denmark and Israel (SC)
  • 01 May 2015 V212 is still in phase III trials for Herpes zoster (Prevention) in countries worldwide
  • 02 Apr 2015 Merck completes enrolment in a phase III trial for Herpes zoster (Prevention) in the US, Argentina, Colombia, Ecuador, Puerto Rico, Belgium, Bulgaria, Estonia, India, South Korea, Spain, Germany, Czech Republic, UK, Austria, Lithuania, Greece and Italy (EudraCT2010-023156-89; NCT01254630)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top